HCPCS Codes Similar to V2

HCPCS Codes Similar to “V2” Code.
Demonstration modifier 2

V1 Demonstration modifier 1 Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON	V3 Demonstration modifier 3 Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON
V4 Demonstration modifier 4 Code added date: 20201001 Code effective date: 20201001 TXT \| PDF \| XML \| JSON	G9072 Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i, or stage iia-iib; or t3, n1, m0; and er and pr negative; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON
G9077 Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t1-t2c and gleason 2-7 and psa < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON	G9084 Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-3, n0, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON
G9086 Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-4, n1-2, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON	G9090 Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-2, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON
G9092 Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-3, n1-2, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON	G9114 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage ia-b (grade 2-3); or stage ic (all grades); or stage ii; without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) Code added date: 20060101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON
G9134 Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage i, ii at diagnosis, not relapsed, not refractory (for use in a medicare-approved demonstration project) Code added date: 20070101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON	G9486 Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology Code added date: 20160401 Code effective date: 20180101 TXT \| PDF \| XML \| JSON
G9487 Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology Code added date: 20160401 Code effective date: 20180101 TXT \| PDF \| XML \| JSON	G9488 Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology Code added date: 20160401 Code effective date: 20180101 TXT \| PDF \| XML \| JSON